iifl-logo

Syngene International Ltd Historical Data

630.65
(-0.32%)
Oct 8, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Syngene International Ltd Historical Data

08/09/2025calendar-icon
08/10/2025calendar-icon
Date
Open(₹)
High(₹)
Low(₹)
Close(₹)
No. Of Trades(₹)
Total Turnover(₹)
Deliverable Quantity(₹)

08-Sep-2025

651.6

655.5642.35649.514,34025,82,42,931.852,21,618

09-Sep-2025

650

653.5628644.630,96053,45,05,252.054,08,140

10-Sep-2025

645.2

655.75645652.5512,86519,98,22,064.251,65,972

11-Sep-2025

655

664651.7566117,83241,56,38,876.33,78,984

12-Sep-2025

664.1

666.85658.9664.1514,26566,21,82,116.66,37,269

15-Sep-2025

663.4

673.7658.1670.824,11860,66,17,950.555,35,177

16-Sep-2025

670.8

673.9653.8657.2513,25453,92,78,351.855,76,284

17-Sep-2025

660.5

663650.2651.226,51087,69,68,967.79,56,882

18-Sep-2025

652

660649.3657.9510,16826,87,07,394.12,57,523

19-Sep-2025

659

666.75656.3665.4519,36933,58,00,149.63,36,170

22-Sep-2025

666

668650655.314,83232,05,11,431.12,56,946

23-Sep-2025

658

659.1642643.6510,55610,56,49,348.4572,260

24-Sep-2025

643.65

645.45638.55641.159,20732,78,69,011.63,69,414

25-Sep-2025

641.05

642.15635.2636.921,51523,14,37,046.32,04,428

26-Sep-2025

628

633.75608609.4533,83153,80,65,333.454,23,037

29-Sep-2025

612.45

622607.05614.328,98035,38,77,114.153,33,840

30-Sep-2025

614.3

625.75613.35622.8544,90448,83,15,162.24,34,159

01-Oct-2025

623.3

636.45623631.615,78324,03,88,850.951,59,433

03-Oct-2025

631

640.6627.5635.526,64432,33,42,090.33,20,933

06-Oct-2025

635.95

637.85626.9634.515,11743,45,99,143.054,94,730

07-Oct-2025

634.5

641.8631.2632.719,99445,18,74,032.553,75,968

08-Oct-2025

632.4

637.7627.7630.6521,84954,29,48,054.154,85,491

Syngene Intl.: Related NEWS

Syngene Gets FDA Nod on Biocon Park Inspection With VAI Status

The outcome of the inspection has been classified as “Voluntary Action Indicated” or VAI.

15 Jun 2025|09:00 PM
Read More
Syngene Reports ₹1,018 Crore Revenue in Q4 FY25

The purchase is anticipated to enhance Syngene's position in the biologics contract development and manufacturing organization (CDMO) arena, specifically in the US market.

24 Apr 2025|01:21 PM
Read More
Syngene International reports better than expected Q4 results

The company reported an operating EBITDA of ₹343.60 Crore in the quarter four of FY25. It registered a growth of 8.4% on a year-on-year basis.

24 Apr 2025|11:36 AM
Read More
Syngene Boosts Biologics Capacity with US Facility Acquisition

This acquisition will also augment Syngene’s biologics capabilities and further strengthen its global presence.

13 Mar 2025|01:40 PM
Read More
Syngene Reports 18% Profit Surge in Q3, Revenue Up 10.6%

The company's revenue from operations also grew healthily, up by 10.6% YoY to ₹943 crore, as against ₹853.5 crore in Q3 FY24.

24 Jan 2025|12:45 PM
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.